health
STAT+: Novartis doubles down on molecular glue strategy
Why this matters: health reporting relevant to everyday decisions and well-being.
Want to stay on top of the science and politics driving biotech today?&#x A0;Sign up&#x A0;to get our biotech newsletter in your inbox. Medicare drug spending is climbing faster than expected, driven by surging use of GLP-1 medicines and ongoing fallout from Democrats’ Part D redesign. Also, Enliven’s leukemia drug has encouraging early data, Novartis is expanding its molecular glue ambitions, and Sono Thera raised $125 million to advance an ultrasound-based approach to gene delivery.Continue to STAT+ to read the full story…
Article preview — originally published by STAT News. Full story at the source.
Read full story on STAT News →
More top stories
Aggregated and edited by the Scoop newsroom. We surface news from STAT News alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop